

ARTICLE OPEN



ACUTE LYMPHOBLASTIC LEUKEMIA

Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia

Kimberly B. Johansson^{1,2}, Megan S. Zimmerman³, Iryna V. Dmytrenko¹, Feng Gao⁴ and Daniel C. Link¹✉

© The Author(s) 2023

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype *MDM2* and *TP53*, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes *BAX* and *BBC3*, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.

Leukemia (2023) 37:2356–2366; <https://doi.org/10.1038/s41375-023-02057-x>

INTRODUCTION

There is an unmet need for improved therapies to treat T-cell acute lymphoblastic leukemia (T-ALL), given the high rate of relapse and poor outcomes, especially in adults [1, 2]. Activating *NOTCH1* mutations are present in 60–70% of T-ALL cases [3], with inactivating mutations in *FBXW7*, a negative regulator of Notch signaling, present in an additional 15% of patients [4–8]. Although activation of Notch signaling and its downstream target c-Myc can trigger apoptosis through the ARF-MDM2-p53 tumor suppressor pathway, apoptosis is frequently inactivated in T-ALL through homozygous deletions of the *CDKN2A* locus encoding ARF in 80% of patients [9]. ARF antagonizes the function of MDM2, a nuclear-localized E3 ubiquitin ligase which targets p53 for degradation [10]. Inhibition of MDM2 ultimately leads to p53-mediated growth suppression and/or apoptosis [11]. Importantly, wildtype p53 expression is retained in more than 95% of primary T-ALL cases and 75% of relapsed cases [12, 13]. Based on these genomic data, we hypothesized that restoring the p19(ARF)-MDM2-p53 tumor suppressor pathway through MDM2 inhibition would increase p53 expression and lead to apoptosis in T-ALL.

In this study, we show that idasanutlin, a second generation small molecule inhibitor of MDM2, induces expression of pro-death BH3 domain family members *BAX* and *BBC3* (PUMA) but only modest apoptosis. Based on these observations, we

hypothesized that inhibition of anti-apoptotic proteins would be synergistic with MDM2 inhibition in T-ALL. Navitoclax is an orally available investigational small molecule inhibitor of Bcl-2 family proteins [14]. Navitoclax acts as a BH3 mimetic within the BH3-binding domain of Bcl-2 anti-apoptotic proteins [15]. As T-ALL response to navitoclax has been transient [16, 17], we hypothesized improved efficacy using a combination of navitoclax and idasanutlin. For these studies, we used a panel of T-ALL PDX lines with the goal to recapitulate the most frequent genomic alterations in T-ALL and also include cases of early T-cell precursor ALL (ETP-ALL), an important leukemia subtype with distinct genomics and very poor clinical prognosis. We demonstrate that combination of BH3 and MDM2 inhibition acts synergistically to kill T-ALL cell lines and patient-derived xenografts (PDX) both in vitro and in vivo.

MATERIALS AND METHODS**T-ALL cell lines and PDX cells**

The human T-ALL MOLT-3 cell line was previously kindly provided by the lab of Dr. Grant Challen (Washington University School of Medicine, St. Louis, MO, USA) [18]. MOLT-3 cells were maintained in ATCC-formulated RPMI-1640 Medium containing 10% heat-inactivated fetal bovine serum with 100 U/ml penicillin and streptomycin (#15140122; Gibco) at 37 °C with 5% CO₂ in a humidified incubator. The mouse T-ALL PDX lines DFC112,

¹Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. ²Medical Scientist Training Program, Washington University School of Medicine, St. Louis, MO, USA. ³Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA. ⁴Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. ✉email: danielclink@wustl.edu

Received: 18 January 2023 Revised: 24 September 2023 Accepted: 4 October 2023

Published online: 14 October 2023

DFCI15, DFAT28537, DFAT27681, and CBAT27299 were previously established and kindly provided by the cBioPortal (Dana Farber Cancer Institute, Boston, MA, USA) [19, 20]. The PDX cells were maintained in StemSpan™ SFEM II (#9655, Stem Cell Technologies), penicillin-streptomycin (100 U/ml), human IL-2 (0.2 IU/ml), human IL-7 (10 ng/ml), and human stem cell factor (50 ng/ml).

CRISPR/Cas9 knockout

For generation of knockout cells using the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system, single-guide RNA (sgRNAs) targeting *TP53* or the AAVS1 safe-harbor locus were purchased (Integrated DNA Technologies) and mixed with recombinant Cas9 protein (IDT), incubated at room temperature to generate ribonucleoprotein complexes, and transferred into MOLT-3 cells using the Neon transfection system at 1350 V, 35 ms, 1 pulse, following manufacturer recommendations. Isogenic clones were generated through outgrowth following single cell sorting. Insertion/deletion status was assessed by next-generation sequencing of the target locus on the Illumina MiSeq platform and analyzed using CRISPResso2 [21], and knockout was confirmed through immunoblotting 6 h following x-ray irradiation (10 Gray, KUBTEC XCELL 50). Cell lines are monitored with STR profiling and mycoplasma testing.

Quantitative real-time PCR and immunoblotting

The methods followed for real-time PCR and immunoblotting were as previously described in [22] and are detailed in the Supplementary Methods, including specific reagents and antibodies.

Proliferation and caspase activity assays

T-ALL cell lines and PDX cells were subjected to CellTiter-Glo assay (#PRG9242; Promega) and Caspase-Glo 3/7 assay (#PRG8091; Promega) as detailed in the Supplementary Methods.

Flow cytometry

T-ALL cell lines and PDX cells were subjected to flow cytometry assessment of cell cycle, apoptosis, and viability as previously described in [23] and are detailed in the Supplementary Methods. In vivo PDX models underwent peripheral blood flow cytometry for human CD45.

In vivo PDX models of T-ALL

All animal studies were approved by the Institutional Animal Care and Use Committee at Washington University in St. Louis under protocol number 20-0495. DFCI12, DFCI15, DFAT28537, and CBAT27299 PDX cells were engrafted into NSG mice and treated with vehicle alone, idasanutlin, and/or navitoclax with hCD45 flow cytometry as described in the Supplementary Methods. Upon evidence of engraftment, mice were stratified by degree of tumor burden, and mice from each tier were randomized equally into treatment cohorts. These random groups were treated with a proportional mixture of both vehicles, idasanutlin (RG7388, Roche investigational basis) (40 mg/kg by oral gavage daily on a 5-days-on 2-days-off schedule for 14 days), navitoclax (ABT-263, Chemgood C-1009 [24, 25]) (100 mg/kg by oral gavage daily for 14 days), or combination therapy. Idasanutlin was sonicated into suspension in Roche GTX011795 solvent (Water 97.8% + Hydroxypropyl cellulose 2% + Polysorbate 80 0.1% + Methyl paraben 0.09% + Propyl paraben 0.01% + Sodium acetate 0.0072% + Acetic acid, glacial 0.0569%). Navitoclax was formulated per manufacturer's instructions by sonicating into suspension in 60% phosal 50 propylene glycol, 30% polyethylene glycol 400, and 10% ethanol. Two independent experiments were performed with cohort sizes ranging from 15 (3–4 per treatment) to 31 (7–8 per treatment), for a pooled minimum of $n = 10$ per treatment, per PDX line. Minimum cohort size determined based on estimated effect size following pilot experiment. Based on the law of diminishing returns [26] recommended that a degree of freedom (DF) of 10–20 associated with error term in an analysis of variance (ANOVA) would be adequate to estimate preliminary information with a good precision.

Statistical analyses

Statistical testing was performed using Prism (version 9, GraphPad Software). The between-group differences in tumor burden were compared using unpaired Student's *t* test for independent samples or two-way analysis of variance for repeated measurement data. Model diagnosis was performed graphically based on residuals from each model. The differences in survival

were summarized using Kaplan–Meier curves and compared by log-rank tests. Synergy was calculated in vitro using SynergyFinder 2.0 to determine a ZIP (zero interaction potency) score [27, 28]. Synergy was calculated for in vivo studies using a modified Bliss Independence test, analyzing average daily change between the dual therapy and the most effective single agent therapy. All experiments were performed with at least two independent experiments, each in triplicate, unless otherwise noted. Sample size is specified in each panel with all data points plotted individually for $n < 5$. All data are presented as mean \pm standard error of the mean. A *p* value of < 0.05 was considered significant.

RESULTS

Idasanutlin has p53-dependent activity against T-ALL cells

We hypothesized that *TP53*-sufficient T-ALL is sensitive to MDM2 inhibition. To test this hypothesis, we initially studied MOLT-3 cells, an immortalized T-ALL cell line with wildtype *TP53*, and generated isogenic cell lines edited at *TP53* or the AAVS1 safe-harbor locus (control). After identifying frameshift indels in each allele by sequencing, we validated p53 loss by assessing protein level following x-ray irradiation. We observed strong induction of p53 protein in the AAVS1-edited control lines, but completely absent p53 in both *TP53* knockout (KO) lines tested, each of which carried different indel mutation combinations (Fig. S1A).

MOLT-3 control cells exhibited a dose-dependent sensitivity to idasanutlin, whereas both p53 KO cell lines were resistant (Fig. 1A). As predicted, treatment with idasanutlin resulted in stabilization and accumulation of p53 protein in only the control line (Fig. 1B). Ultimately, idasanutlin treatment induced apoptosis of MOLT-3 control cells but not the p53 knockout lines, as evidenced by increased caspase-3/7 activity (Fig. 1C) and by cell surface annexin-V expression (Fig. 1D, E). Idasanutlin treatment also resulted in strong induction of the pro-apoptotic p53 target genes *BBC3* and *BAX* at both the RNA and protein level, which was lost in p53 knockout cells (Fig. 1F, G). In order to confirm MDM2 as a relevant target, we also treated cells with the chemically distinct MDM2 inhibitor MI-773 (SAR405838). Treatment with this alternative compound induced a p53-dependent decrease in cell number (Fig. S1B) as well as induction of apoptosis as indicated by increased activated caspase-3/7 limited to the control line (Fig. S1C).

We next assessed the response of DFCI12, a T-ALL PDX, to idasanutlin. DFCI12 cells carry an activating *NOTCH1* mutation but are wildtype for *TP53* (Table 1). DFCI12 cells were sensitive to 1.5 μ M idasanutlin, a higher dose than that required for MOLT-3 cells, but within the range of idasanutlin achieved in the serum in vivo (Fig. 2A) [29, 30]. In DFCI12 cells, treatment with idasanutlin induced expression of the *TP53* target genes *BAX*, *BBC3* (Puma), and *CDKN1A* (p21) at the RNA (Fig. 2B–D) and protein levels (Fig. 2E–H), and resulted in a modest increase in apoptosis (Fig. 2I, J). Consistent with increased *CDKN1A* expression, idasanutlin treatment induced a modest, but significant, decrease in cycling cells, with an increase in cells in the G1 phase and a decrease in cells in the S–G2–M phases of the cell cycle (Fig. 2K, L). Together, these data suggest that MDM2 inhibition has modest activity against T-ALL.

Idasanutlin and navitoclax demonstrate synergistic activity against T-ALL PDX lines

The induction of expression of pro-death BH3 domain family members *BAX* and *BBC3* suggested that MDM2 inhibition may prime T-ALL cells for induction of apoptosis after treatment with inhibitors of pro-survival BH3 domain proteins, such as venetoclax (targeting Bcl-2) or navitoclax (targeting Bcl-2 and Bcl-xL). Since a prior study showed increased activity of navitoclax compared to venetoclax in T-ALL [31], we next assessed the response of DFCI12 cells to idasanutlin alone, navitoclax alone, or the combination. Whereas treatment with navitoclax or idasanutlin alone modestly inhibited DFCI12 cell growth, combination therapy resulted in complete killing (Fig. 3A). Indeed, combination therapy strongly induced




Fig. 1 Idasanutlin has p53-dependent activity against T-ALL immortalized cell lines. **A** Cell number of isogenic AAVS-1 targeted (control) or *TP53*^{-/-} (p53 KO) MOLT-3 cells cultured with idasanutlin (30, 60, 90 nM) over 72 h. **B** Protein levels of p53 and β -actin in MOLT-3 control or p53 KO lines after 24 h of idasanutlin treatment. **C** Relative caspase-3/7 activity over 48 h of vehicle or idasanutlin treatment. **D** Representative Annexin V apoptosis and Sytox viability staining of MOLT-3 control (left) or p53 KO (right) cells following 48 h of treatment. **E** Percent apoptotic cells measured by Annexin V positivity following 48 h of treatment. **F** Expression levels of p53 target gene *BAX* RNA (left) and Bax protein (center representative immunoblot, right quantification relative to β -actin) in MOLT-3 cell lines after 24 h of idasanutlin treatment. **G** Expression levels of p53 target gene *BBC3* RNA (left) and Puma protein (center representative immunoblot, right quantification relative to β -actin) in MOLT-3 cell lines after 24 h of idasanutlin treatment. All experiments performed in triplicate with at least two independent experiments. Error bars represent SEM (**** ≤ 0.0001 , *** ≤ 0.001 , ** ≤ 0.01 , * ≤ 0.05 compared to DMSO). **A**, **C** Two-way ANOVA, **E–G** unpaired *t*-test.

apoptosis, with nearly all cells after 24 h showing Annexin V cell surface staining (Fig. 3B, C). A formal dose-response matrix was generated to assess the synergy of the drug combination in T-ALL cell killing (Fig. 3E). Synergy was assessed by ZIP (zero interaction potency), a statistical method developed by Yadav et al. that compares the change in potency of individual dose response curves

in the presence of a second agent [27]. Generally, a ZIP score greater than 10 is considered evidence for synergy. Idasanutlin and navitoclax combination therapy had an overall ZIP synergy score of 16.9 ± 1.35 . The most synergistic area scores of up to 51.8 were observed at 0.75–6 μ M idasanutlin and 0.3–1 μ M navitoclax, which are clinically achievable drug concentrations.

Table 1. T-ALL PDX selected clinical and molecular characteristics.

Name	WHO classification	Sex	Age	NOTCH1	FBXW7	CDKN2A	TP53	Cytogenetics	Treatment phase when sampled
DFCI12	T-ALL	M	16.11	L1574P, T432M			Wildtype	47,XY,+8,add(9)(p13)	Unknown
DFCI15	T-ALL	M	6.11	F1592S, P2514X		Deleted	Wildtype	46,XY	Untreated
DFAT-28537	T-ALL	M	25	F1592S	R465H	Deleted	Wildtype	Unknown	Untreated
DFAT-27681	T-ALL ETP	M	23			Deleted	Wildtype	46,XY,t(1;12)(q21;p13)	Relapse post-allogeneic HSCT
CBAT-27299	T-ALL ETP	M	5				Wildtype	46,XY	Untreated

To determine whether the sensitivity to idasanutlin and navitoclax dual therapy extended beyond DFCI12 cells, we treated a panel of four additional T-ALL PDX lines in vitro with vehicle alone, idasanutlin alone, navitoclax alone, or dual therapy. Including DFCI12 cells, the five different PDX lines represent a range of T-ALL genetics (Table 1). *NOTCH1* and/or *FBXW7* mutations are present in three lines; *CDKN2A* biallelic loss is present in three lines; and all lines are wildtype for *TP53*. Two lines are ETP-ALL with wildtype *NOTCH1*, *FBXW7*, and *TP53*. For all five PDX lines tested, in vitro dual treatment led to robust cell death within 48 h. For two of the cell lines tested, in vitro treatment with 1 μ M navitoclax alone was also highly efficacious (Fig. 3G–J). Additionally, we treated each of these lines with a formal dose-response matrix to assess potential synergic activity of idasanutlin and navitoclax in combination. We identified that of the five lines tested, one suggested an additive effect of the therapy and the remaining 4 demonstrated synergic activity with ZIP scores ranging from 10.3–16.9 (Figs. 3F and S2A–D). Additionally, while the MOLT-3 T-ALL control line was responsive to combination therapy, the p53 knockout MOLT-3 line did not demonstrate a response with a ZIP synergy score of -1.48 ± 2.61 (Fig. S2E, F), suggesting the synergic effect of therapy is p53-dependent.

Venetoclax is another BH3 mimetic of interest, which inhibits Bcl-2 but not Bcl-xL. Prior studies examining venetoclax in combination with MDM2 inhibition in the context of acute myeloid leukemia have shown promising results [32]. However, previous studies have shown that a majority of T-ALL samples have increased sensitivity to navitoclax compared to venetoclax [31, 33]. To directly assess the activity of venetoclax, we treated each T-ALL PDX line with venetoclax alone, idasanutlin alone, or the combination. At clinically relevant doses of venetoclax [34], we observed a statistically significant, but modest, growth inhibition with all 5 T-ALL PDX lines that was potentiated by idasanutlin (Fig. 3D, K–N). We next tested a dose-response matrix, which showed which showed clear synergy with idasanutlin in a single T-ALL PDX line (DFAT27681), with an additive effect in 3 lines, and no response in DFC12 cells (Figs. S3 and 3F).

There is evidence for increased JAK/STAT signaling in a subset of T-ALL [35, 36], with in vitro studies showing activity of JAK2 inhibitors alone or in combination with dexamethasone [37] or MDM2i [38] in *JAK3*-mutated T-ALL. To directly assess the activity of JAK2 inhibitors, we treated the T-ALL PDX lines with ruxolitinib (a competitive inhibitor of the JAK1 and JAK2 kinases) alone, idasanutlin alone, or the combination. At clinically relevant doses [39, 40], ruxolitinib treatment induced a statistically significant, but modest, growth suppression in all T-ALL PDX lines, which was potentiated by the addition of idasanutlin (Fig. S4A–E). However, analysis of dose-response matrix data showed no strong synergic effect for the combination of ruxolitinib and idasanutlin in any of the five T-ALL PDX lines tested (Figs. S4F–J and 3F). Collectively, these data suggest that the combination of navitoclax plus idasanutlin provides more consistent and potent synergistic killing of T-ALL PDX lines than the combination of venetoclax with idasanutlin or ruxolitinib with idasanutlin.

Transcriptional characterization of treated PDX lines

To explore mechanisms of synergy, we performed RNA sequencing on DFCI12 cells treated with idasanutlin alone, navitoclax alone, the combination, or vehicle-only for 16 h, when the majority ($\geq 70\%$) of cells were viable and non-apoptotic as measured by Annexin-V staining (Fig. S5). Principal components analysis of these samples reveals a close clustering of navitoclax single treatment with control, while idasanutlin alone and dual therapy are each distinct (Fig. 4A). Accordingly, there was only one significantly differentially expressed gene induced by navitoclax treatment alone, which is consistent with navitoclax primarily acting post-transcriptionally to activate apoptosis (Fig. 4B and Table S1). Idasanutlin treatment led to the significant




Fig. 2 Idasanutlin has modest in vitro activity against a T-ALL PDX line. **A** Cell number of the DFCI12 cells over 72 h of treatment with idasanutlin (1.5 μM) or vehicle control. Expression of *BAX* (**B**), *BBC3* (**C**), and *CDKN2A* (**D**) mRNA 24 h into treatment; data are normalized to β-actin. **E** Representative immunoblots for Bax, Puma, p21 and β-actin following 24 h of treatment. Quantification of protein levels of Bax (**F**), Puma (**G**), and p21 (**H**) relative to β-actin at 24 h. **I** Representative flow cytometry plots for Annexin V staining of vehicle (left) and idasanutlin (right) cells following 48 h of treatment. **J** Percent apoptotic cells measured by Annexin V positivity following 48 h of treatment. **K** Representative flow cytometry distribution for FxCycle Ki-67 staining of vehicle (left) and idasanutlin (right) following 48 h of treatment. **L** Cell cycle plots following 48 h of treatment. All experiments performed in triplicate with at least two independent experiments. Error bars represent SEM (**** ≤ 0.0001, *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05 compared to DMSO). **A** Two-way ANOVA, **B–D**, **F**, **G**, **J**, **L** unpaired t-test.




Fig. 3 The combination of idasanutlin and navitoclax has synergistic activity against T-ALL PDX lines in vitro. **A** DFC12 cells were treated in vitro over 72 h with vehicle, idasanutlin (1.5 μ M), navitoclax (1 μ M), or combination therapy and cell number quantified. **B** Representative flow plot for Annexin V staining of vehicle (left) and dual-treated (right) cells following 48 h of treatment. **C** Percent apoptotic cells by Annexin V positivity following 48 h of treatment. **D** DFC12 cells were treated in vitro over 72 h with vehicle, idasanutlin (1.5 μ M), venetoclax (1 μ M), or combination therapy and cell number was quantified. **E** DFC12 cells were treated with increasing doses of idasanutlin (vehicle, 6 nM, 60 nM, 188 nM, 375 nM, 750 nM, 1.5 μ M, 3 μ M, 6 μ M) and navitoclax (vehicle, 100 nM, 200 nM, 300 nM, 500 nM, 500 nM, 1 μ M) to generate a dose-response matrix and evaluate for ZIP synergy score with SynergyFinder 2.0. Representative panel from two independent experiments. **F** Zip synergy scores for the indicated T-ALL PDX line based on dose-response matrix data testing the indicated drug combination. Primary data are presented in Figs. S2–4. DFCI15 (**G**), DFAT28537 (**H**), DFAT27681 (**I**), or CBAT27299 (**J**) cells were treated in vitro over 72 h with vehicle, idasanutlin (1.5 μ M), navitoclax (1 μ M), or combination therapy and cell number quantified. DFCI15 (**K**), DFAT28537 (**L**), DFAT27681 (**M**), or CBAT27299 (**N**) cells were treated in vitro over 72 h with vehicle, idasanutlin (1.5 μ M), venetoclax (1 μ M), or combination therapy and cell number quantified. All experiments performed in triplicate with at least two independent experiments. Error bars represent SEM (**** ≤ 0.0001 , *** ≤ 0.001 , ** ≤ 0.01 , * ≤ 0.05 compared to DMSO). **A** Two-way ANOVA, **C** unpaired *t*-test, **D** two-way ANOVA, **E**, **F** Zero Interaction Potency Score, **G–N** two-way ANOVA.

upregulation of 73 genes, including known p53 target and cellular stress response genes, such as *INKA2*, *BAX*, *BBC3*, and *CDKN1A* (Fig. 4C, D and Table S1). Indeed, gene set enrichment analysis identified the Hallmark p53 pathway as the top upregulated pathway in idasanutlin-treated cells (Fig. 4F, G). Finally, a total of 217 significantly differentially expressed genes were identified comparing idasanutlin with combination treated cells (Table S1). The top upregulated gene expression pathway in combination treated cells compared to idasanutlin alone was the Hallmark TNF α signaling via NF κ B (Fig. 4H). Indeed, marked increased expression of certain known NF κ B target genes was observed, including *EGR1*, *EGR3*, *FOS*, *FOSB*, and *GADD45B* (Fig. 4E).

The combination of idasanutlin and navitoclax is highly active in human T-ALL xenotransplantation models

Having observed strong in vitro activity against a panel of T-ALL PDX lines, we next assessed the in vivo response of four different T-ALL xenografts to dual idasanutlin and navitoclax treatment. For each line, human T-ALL cells were injected into immunodeficient mice, and following engraftment, mice were randomized into treatment groups. Mice were treated for 14 days before withdrawal of therapy, and tumor burden as well as survival were analyzed (Fig. 5A). Combination therapy was tolerated in the mice, with minor transient weight loss observed.

Treatment with navitoclax induced a significant decrease in T-ALL burden in all four xenotransplants (Fig. 5B–I). Treatment




Fig. 4 Transcriptional characterization of treated PDX lines. **A** Principal components analysis clustering of transcriptomes from vehicle only, idasanutlin (1.5 μ M), navitoclax (300 nM), and combination therapy-treated cells. Differential expression of cells treated with: idasanutlin compared to vehicle (**B**), navitoclax compared to vehicle (**C**), combination compared to vehicle (**D**), or combination compared to idasanutlin only (**E**). Significantly downregulated genes are shown in blue and upregulated in red. Select p53-pathway genes of interest are annotated. All significant enriched Human Molecular Signatures Database (MSigDB) Hallmark pathways for idasanutlin compared to vehicle (**F**), combination compared to vehicle (**G**), and combination compared to idasanutlin only (**H**). No Hallmark pathways were significantly altered in navitoclax relative to vehicle. Three independent samples were analyzed for each condition. Genes are reported as significantly differentially expressed when FDR-adjusted p value ≥ 0.5 and log fold change ≥ 2 or ≤ -2 .


with idasanutlin alone induced a significant decrease in T-ALL burden in 3 of 4; the non-responding xenograft was an ETP-ALL (Fig. 5H, I). Finally, a marked response to combination treatment with idasanutlin and navitoclax was seen in all four T-ALL xenografts, exceeding a predicted additive effect based on monotherapy response. This combination was found to be synergistic in each case based on a modified Bliss Independence test, analyzing average daily change in tumor burden for synergy interaction. In addition, overall survival was significantly increased in the combination treatment group.

DISCUSSION

T-ALL is an aggressive hematologic malignancy that comprises 15% of pediatric ALL and 25% of adult ALL [3, 41]. Current treatment consists of intense chemotherapy that is associated with acute and chronic life-threatening or debilitating toxicities [42]. Five-year event-free survival is 70–75% for children, 30–40% for

adults under 60, and less than 10% for adults over age 60 [43]. The prognosis after relapse is dismal, with 3-year event-free survival of only 10–15% [1, 44–46]. Allogeneic hematopoietic cell transplantation (HCT) may be curative for relapsed T-ALL; however, in the largest study performed to date, overall survival was only 24% after a median follow-up of 2 years [47]. Thus, there remains an unmet clinical need for better T-ALL therapeutics. The present study explores the feasibility of reactivating oncogenic stress sensing and the consequent apoptotic response through combined MDM2 and pro-apoptotic Bcl-2 family protein inhibition.

Notch pathway overactivation is key to T-ALL pathogenesis. MYC is among the numerous target genes activated by Notch1, and has been proposed to be one of the most critical for T-ALL growth and maintenance [48–50]. Increased expression of MYC has been reported in the majority of T-ALL cases [51]. *FBXW7* mutations are present in ~15% of T-ALL patients [3]. In addition to activating Notch1, they also stabilize Myc protein expression through regulation of its ubiquitination [52]. Activation of the



PI3K/AKT pathway is detectable in 70–85% of patients with T-ALL, in roughly 5–10% of cases due to inactivating mutations of *PTEN* [53, 54]. A recent study showed that activation of the PI3K/AKT pathway activates Myc signaling by stabilizing Myc protein expression [51].

Myc is a master transcription factor that regulates up to 15% of genes, including many involved in proliferation and metabolism [55]. However, Myc expression by itself is not sufficient to induce leukemia/lymphoma [11, 56]. Myc, while inducing cellular proliferation, also induces oncogenic stress, resulting in apoptosis

Fig. 5 The combination of idasanutlin and navitoclax is highly active in human T-ALL xenotransplantation models. **A** Each human T-ALL xenograft was injected into NSG mice and allowed to engraft. Once engraftment of T-ALL was observed, mice were randomized to one of four treatments: (1) vehicle alone; (2) idasanutlin 40 mg/kg by oral gavage daily on a 5-days-on 2-days-off schedule for 14 days; (3) navitoclax 100 mg/kg by oral gavage daily for 14 days; (4) combined idasanutlin and navitoclax. Two independent experiments were performed with cohort sizes ranging from 15 (3–4 per treatment) to 31 (7–8 per treatment). Survival was tabulated and leukemic burden was measured in the blood by flow cytometry for human CD45⁺ cells for the DFC112 (**B, C**), DFC115 (**D, E**), DFAT28537 (**F, G**), and CBAT27299 (**H, I**) lines. Two independent experiments were performed per line, with cohort size minimum $n = 10$. Error bars represent SEM (**** ≤ 0.0001 , *** ≤ 0.001 , ** ≤ 0.01 , * ≤ 0.05 compared to vehicle). Variance in tumor burden was similar between the treatment groups. **B, D, F, H** Pairwise comparisons, **C, E, G, I** Synergy assessed with modified Bliss Independence test, analyzing average daily change in tumor burden for synergy interaction.

[57]. *TP53* is rarely mutated in T-ALL, even in relapsed patients [12, 13]. Here, we demonstrated that derepression of p53 activity through the prevention of MDM2-p53 association with the second-generation MDM2 inhibitor idasanutlin has modest p53-dependent activity against T-ALL PDX as a single agent therapy.

Increased Myc expression can induce oncogenic stress through multiple mechanisms, including induction of DNA replicative stress and ribosome biogenesis stress [52, 58]. Whether these pathways are activated, and to what degree, in T-ALL is an important area of future investigation. Moreover, studies to further define the relative contributions of different BH3 domain proteins in the regulation of apoptosis in T-ALL are worthwhile, since they may help optimize anti-BH3 domain therapy in this cancer.

Given the evidence of upregulation of pro-apoptotic proteins in response to idasanutlin exposure, we explored a rational combination of idasanutlin and navitoclax, a Bcl-2/Bcl-xL inhibitor. We observed strong p53-dependent synergistic activity, and induction of apoptosis by idasanutlin and navitoclax in vitro against a panel of T-ALL PDX lines. RNA sequencing of treated PDX cells was consistent with a convergence on apoptosis, with idasanutlin inducing gene expression level upregulation of the p53 pathway and navitoclax leading to minimal additional RNA level changes. The addition of navitoclax to idasanutlin in combination therapy was associated with a significant increase in NF- κ B pathway gene expression. Whether NF- κ B signaling directly contributes to induction of apoptosis in this setting will require further study.

We demonstrated that idasanutlin and navitoclax have strong activity in vivo in human T-ALL xenotransplantation models. Combination therapy demonstrated synergistic activity in suppression of tumor burden and increased survival in a panel of four T-ALL PDX. Hence, the present work provides strong support for therapeutic efficacy of simultaneous MDM2 inhibition and Bcl-2 family protein inhibition against T-ALL. There is concern that the dose-limiting thrombocytopenia observed with navitoclax treatment due to on-target Bcl-xL inhibition in circulating platelets may limit its use in the clinic [17, 59, 60]. Venetoclax, which does not target Bcl-xL, is more widely used in cancer treatment at present. An ongoing clinical trial evaluating the combination of both venetoclax and navitoclax in relapsed ALL, including T-ALL, is underway (NCT05192889) and should provide data on safety and tolerability. Additionally, there is an ongoing trial of idasanutlin in combination with venetoclax in patients under 30 years of age with refractory/relapsed neuroblastoma, *r/r* AML, and *r/r* ALL (NCT04029688), although T-ALL is a specific exclusion criterion for this study. However, a prior study showed that navitoclax has superior activity in T-ALL compared to venetoclax [31]. We observed that the combination of navitoclax and idasanutlin is superior to venetoclax and idasanutlin, providing more potent and consistent synergistic killing. All three agents, navitoclax, venetoclax, and idasanutlin, share some overlap in safety profile including gastrointestinal toxicity and myelosuppression [16, 29, 34]. Of note, the synergistic response of T-ALL to navitoclax and idasanutlin may permit the use of lower, more tolerable, doses of navitoclax while maintaining on-target Bcl-xL inhibition.

A limitation of this study remains that in vitro only five PDX lines were assessed, and in vivo only PDX lines from four different patients were investigated. Although our findings were robust across these lines, they cannot represent the complete diversity of all T-ALL mutational profiles. However, the PDX lines selected are broadly representative, harboring a combination of frequent *NOTCH1* and/or *FBXW7* mutations, biallelic *CDKN2A* loss, and wildtype *TP53*; all T-ALL genetic hallmarks. These lines are representative and generalizable to T-ALL genomics across a majority of cases. Acknowledging this limitation, the strong and robust response across these lines, which carry commonly recurring T-ALL mutations, suggests that human trials for idasanutlin and navitoclax combination therapy in wildtype *TP53* cases are merited.

DATA AVAILABILITY

All datasets generated during the current study are available from the corresponding author upon reasonable request. Raw reads and processed RNA-seq gene counts generated for this study are available at Gene Expression Omnibus accession number GSE240444.

REFERENCES

- Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study. *J Clin Oncol*. 2008;26:3971–8.
- Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E. Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. *Leuk Lymphoma*. 2019;60:1171–8.
- Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience. *J Clin Oncol*. 2003;21:3616–22.
- Weng AP. Activating mutations of *NOTCH1* in human T cell acute lymphoblastic leukemia. *Science*. 2004;306:269–71.
- Asnafi V, Buzyn A, Le Noir S, Baleydiere F, Simon A, Beldjord K, et al. *NOTCH1*/*FBXW7* mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. *Blood* 2009;113:3918–24.
- Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, et al. The impact of *NOTCH1*, *FBW7* and *PTEN* mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Leukemia*. 2009;23:1417–25.
- Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, et al. Prognostic implications of *NOTCH1* and *FBXW7* mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. *J Clin Oncol*. 2009;27:4352–6.
- Park M-J, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, et al. *FBXW7* and *NOTCH1* mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. *Br J Haematol*. 2009;145:198–206.
- Hebert J, Cayuela J, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p15INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. *Blood*. 1994;84:4038–44.
- Dai M-S, Shi D, Jin Y, Sun X-X, Zhang Y, Grossman SR, et al. Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. *J Biol Chem*. 2006;281:24304–13.
- Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. *Genes Dev*. 1999;13:2658–69.

12. Gustafsson B, Axelsson B, Gustafsson B, Christensson B, Winiarski J. MDM2 and P53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. *Pediatr Hematol Oncol.* 2001;18:497–508.
13. Comeaux EQ, Mullighan CG. *TP53* mutations in hypodiploid acute lymphoblastic leukemia. *Cold Spring Harb Perspect Med.* 2017;7:a026286.
14. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res.* 2008;68:3421–8.
15. Mérimo D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C, et al. Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. *Blood.* 2012;119:5807–16.
16. de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, et al. Safety and efficacy of navitoclax, a BCL-2 and BCL-X_L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. *Leuk Lymphoma.* 2020;62:1–9.
17. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumor activity. *Lancet Oncol.* 2010;11:1149–59.
18. Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. *J Natl Cancer Inst.* 1972;49:891–5.
19. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal.* 2013;6:p11.
20. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012;2:401–4.
21. Clement K, Rees H, Canver MC, Gehrke JM, Farouni R, Hsu JY, et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. *Nat Biotechnol.* 2019;37:224–6.
22. Yao J-C, Oetjen KA, Wang T, Xu H, Abou-Ezzi G, Krambs JR, et al. TGF- β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche. *J Clin Invest.* 2022;132:e154092.
23. Warren JT, Cupo RR, Wattanasirikul P, Spencer DH, Locke AE, Makaryan V, et al. Heterozygous variants of *CLPB* are a cause of severe congenital neutropenia. *Blood.* 2022;139:779–91.
24. Domínguez-Bautista JA, Acevo-Rodríguez PS, Castro-Obregón S. Programmed cell senescence in the mouse developing spinal cord and notochord. *Front Cell Dev Biol.* 2021;9:587096.
25. Ahire C, Nyul-Toth A, DelFavero J, Gulej R, Faakye JA, Tarantini S, et al. Accelerated cerebrovascular senescence contributes to cognitive decline in a mouse model of paclitaxel (Taxol)-induced chemobrain. *Aging Cell.* 2023;22:e13832.
26. Mead R. *The design of experiments: statistical principles for practical applications.* Cambridge, England; New York: Cambridge University Press; 1988.
27. Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose an interaction potency model. *Comput Struct Biotechnol J.* 2015;13:504–13.
28. Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. *Nucleic Acids Res.* 2020;48:W488–93.
29. Yee K. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: results from an idasanutlin phase 1/1b study. *Leuk Res.* 2021;100:106489.
30. Jamois C, Anders D, Beckermann BM, Genevray M, Mundt K, Petry C, et al. Contribution of idasanutlin exposure to safety, pharmacodynamics and clinical response of patients with acute myeloid leukemia treated with idasanutlin + cytarabine in phase I and III studies. *Blood.* 2020;136:7–8.
31. Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. *Cancer Discov.* 2014;4:1074–87.
32. Lehmann C, Friess T, Birzele F, Kiialainen A, Dangel M. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in P53 wild-type acute myeloid leukemia models. *J Hematol Oncol.* 2016;9:50.
33. Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. *Blood.* 2016;128:1382–95.
34. Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. *Cancer Discov.* 2021;11:1440–53.
35. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. *Oncogene.* 2013;32:2601–13.
36. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nat Genet.* 2017;49:1211–8.
37. Verbeke D, Gielen O, Jacobs K, Boeckx N, De Keersmaecker K, Maertens J, et al. Ruxolitinib synergizes with dexamethasone for the treatment of T-cell acute lymphoblastic leukemia. *HemaSphere.* 2019;3:e310.
38. Yuan S, Wang X, Hou S, Guo T, Lan Y, Yang S, et al. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. *Leukemia.* 2022;36:370–82.
39. Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Pharmacokinetics and pharmacodynamics of ruxolitinib: a review. *Clin Pharmacokinet.* 2023;62:559–71.
40. Kong T, Yu L, Laranjeira ABA, Fisher DAC, He F, Cox MJ, et al. Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms. *Am J Hematol.* 2023;98:1029–42.
41. Pui C-H. Treatment of acute lymphoblastic leukemia. *N Engl J Med.* 2006;354:166–78.
42. Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group Study CCG-1941. *J Clin Oncol.* 2006;24:3150–6.
43. Gokbuget N, Basara N, Baumann H, Beck J, Brüggemann M, Diedrich H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. *Blood.* 2011;118:3504–11.
44. Van Vlierbergh P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. *J Clin Investig.* 2012;122:3398–406.
45. You MJ, Medeiros LJ, Hsi ED. T-lymphoblastic leukemia/lymphoma. *Am J Clin Pathol.* 2015;144:411–22.
46. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. *Blood.* 2012;119:34–43.
47. Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, et al. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. *Bone Marrow Transplant.* 2017;52:20–7.
48. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. *Proc Natl Acad Sci.* 2006;103:18261–6.
49. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, et al. C-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. *Genes Dev.* 2006;20:2096–109.
50. Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, Beverly L, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-Myc. *Mol Cell Biol.* 2006;26:8022–31.
51. Bonnet M, Loosveld M, Montpellier B, Navarro J-M, Quilichini B, Picard C, et al. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. *Blood.* 2011;117:6650–9.
52. King B, Trimarchi T, Reavie L, Xu L, Mullenders J, Ntziachristos P, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. *Cell.* 2013;153:1552–66.
53. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. *J Clin Investig.* 2008;118:3762–74.
54. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. *Nat Med.* 2007;13:1203–10.
55. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. *Semin Cancer Biol.* 2006;16:253–64.
56. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, et al. Evasion of the P53 tumour surveillance network by tumour-derived MYC mutants. *Nature.* 2005;436:807–11.
57. Morcelle C, Menoyo S, Morón-Duran FD, Tauler A, Kozma SC, Thomas G, et al. Oncogenic MYC induces the impaired ribosome biogenesis checkpoint and stabilizes P53 independent of increased ribosome content. *Cancer Res.* 2019;79:4348–59.
58. Zanutti S, Vanhauwaert S, Van Neste C, Olexiouk V, Van Laere J, Verschuuren M, et al. MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells. *Sci Rep.* 2021;11:14454.
59. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. *Cell.* 2007;128:1173–86.
60. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. *J Clin Oncol.* 2012;30:488–96.

ACKNOWLEDGEMENTS

We are grateful to the patients who contributed samples and clinical information used to derive the PDX lines used in this study. We thank Amy Schmidt for technical assistance and Jackie Tucker-Davis for animal care. We also thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital (St. Louis, MO) for the use of the Siteman Flow Cytometry Core which provided cell sorting expertise; Grant Challen (St. Louis, MO) who provided the MOLT-3 cell line; Roche (Basel, Switzerland) which provided idasanutlin (RG7388) for investigational use; and the Public Repository of Xenografts which provided xenograft lines (Boston, MA). We thank the Genome Technology Access Center at the McDonnell Genome Institute at Washington University School of Medicine for help with genomic analysis, specifically RNA sequencing. The GTAC is partially supported by NCI Cancer Center Support Grant P30 CA91842 to the Siteman Cancer Center from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. This publication is solely the responsibility of the authors and does not necessarily represent the official view of NCRR or NIH. We thank the Genome Engineering & Stem Cell Center at the McDonnell Genome Institute at Washington University School of Medicine for help with mycoplasma testing and STR profiling. This work was supported by the NIH, specifically National Heart, Lung, and Blood Institute National Research Service Award Training Program in Molecular Hematology (T32 HL007088) and National Institute of General Medical Sciences National Research Service Award Training Program-Medical Scientist (T32 GM007200), both to KBJ; the Eunice Kennedy Shriver National Institute of Child Health and Human Development Training Program in Developmental Hematology (T32 HD007499) to MSZ; as well as National Cancer Institute Specialized Programs of Research Excellence in Leukemia (P50 CA171963) to DCL.

AUTHOR CONTRIBUTIONS

KBJ, DCL, and MSZ conceived and designed the experiments, and analyzed the data. KBJ and DCL wrote the manuscript. KBJ, IVD, and MSZ performed the experiments. FG performed synergic statistical analysis for in vivo experiments. All authors reviewed and contributed to the final version of the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41375-023-02057-x>.

Correspondence and requests for materials should be addressed to Daniel C. Link.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023